MedTrace Logo

Efficacy and Safety of Subsequent Cisplatin and Docetaxel in Ovarian Cancer

NCT00772863 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2009-10-29

No results posted yet for this study

Summary

The purpose of this study is to assess the efficacy and the safety of the treatment.

Conditions

  • Ovarian Neoplasms

Interventions

DRUG

docetaxel and cisplatin

4 cycles Cisplatin 100 mg/m2 at every 3 weeks, after Cisplatin 4 cycles of docetaxel 100mg/m2 at every 3 weeks

Sponsors & Collaborators

Principal Investigators

  • Edibe Taylan, MD · Sanofi

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-09-30
Primary Completion
2008-06-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00772863 on ClinicalTrials.gov